Gilead to Offer Senior Notes

March 23, 2011 9:11 AM ET

FOSTER CITY, Calif., Mar 23, 2011 (BUSINESS WIRE) -- Gilead Sciences, Inc. (Nasdaq:GILD) today announced its intention to offer, subject to market and other conditions, senior notes under a shelf registration statement on file with the Securities and Exchange Commission. The interest rate, the maturity dates and other key terms of the offering are to be determined at the time of pricing.

Gilead intends to use the net proceeds from this offering for general corporate purposes, which may include the repayment of certain indebtedness and the repurchase of outstanding common stock pursuant to the company's authorized share repurchase program.

Bank of America Merrill Lynch, J.P. Morgan and Morgan Stanley are acting as joint book-running managers for the offering. The offering of the securities is being made only by means of a prospectus supplement and the accompanying base prospectus, which is part of Gilead's effective shelf registration statement filed with the Securities and Exchange Commission, copies of which may be obtained from:

Bank of America Securities LLC	**J. P. Morgan Securities LLC**	**Morgan Stanley & Co. Incorporated**
Prospectus Department	383 Madison Avenue	180 Varick Street
100 West 33rd Street	New York, NY 10179	New York, NY 10014
New York, NY 10001	Attention: Investment Grade Syndicate Desk	Attention: Prospectus Department
800 294 1322	212 834 4533	866 718 1649

Before you invest, you should read the prospectus supplement and the accompanying base prospectus in Gilead's effective registration statement and other documents Gilead has filed with the Securities and Exchange Commission for more complete information about Gilead and this offering. You may get these documents for free by visiting the Securities and Exchange Commission's website at www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Asia Pacific.

Forward-Looking Statement

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors, including the current market demand for these types of securities and the securities of Gilead and the negotiations between Gilead and the underwriters. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. Other risks that could impact the offering are described in detail in Gilead's Annual Report on Form 10-K for the year ended December 31, 2010 as filed with the U.S. Securities and Exchange Commission, and may be updated by the risk factors set forth in any subsequent filing by Gilead with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead and Gilead assumes no obligation to update any such forward-looking statements.

SOURCE: Gilead Sciences, Inc.

Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715 (Investors)
Amy Flood, 650-522-5643 (Media)
www.gilead.com